NASDAQ:SURF
Delisted
Surface Oncology Inc. Stock News
$1.07
+0 (+0%)
At Close: Dec 06, 2023
Best Penny Stocks To Buy This Week? 3 To Watch Right Now
01:09pm, Tuesday, 20'th Jun 2023
This will likely be another active week for traders. Whether you're trading penny stocks or higher priced shares of companies like Tesla (NASDAQ: TSLA) and Apple (NASDAQ: AAPL), chances are you're pay
Surface Oncology stock flies on $65M stock-for-stock acquisition by Coherus BioSciences
11:01am, Friday, 16'th Jun 2023
Surface Oncology shares jumped by more than 16% on Friday morning after it was revealed the clinical-stage immuno-oncology (I-O) company is being acquired by Coherus BioSciences (NASDAQ:CHRS). The sto
Surface Oncology stock rallies on all-stock acquisition by Coherus
07:51am, Friday, 16'th Jun 2023
Surface Oncology Inc. SURF, +1.37% stock is up 49% in premarket trades on Friday after the cancer drug company agreed to be acquired by Coherus BioSciences Inc. CHRS, +0.56% in a stock-for-stock deal
Data further support SRF388 and SRF114 clinical development programs Data further support SRF388 and SRF114 clinical development programs
- New preclinical data indicate IL-27 induces a gene expression signature that has been associated with resistance to chemotherapy, radiotherapy, and checkpoint inhibition -
Surface Oncology to Participate in the Baird 2022 Global Healthcare Conference
04:30pm, Wednesday, 07'th Sep 2022
CAMBRIDGE, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenv
Surface Oncology to Present New SRF388 Clinical Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
05:00pm, Thursday, 26'th May 2022
– SRF388 demonstrated clinical activity in multiple solid tumor types with three confirmed partial responses across NSCLC, RCC and HCC –
Surface Oncology: Neither Novartis, Nor GSK Or ARKG Is Able To Stop The Decline
08:50am, Wednesday, 25'th May 2022
Surface Oncology has been a major drag for investors. There's no bad news, but there's no good news either.
Surface Oncology to Participate in Upcoming Investor Conferences
04:30pm, Tuesday, 17'th May 2022
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvir
Surface Oncology to Present Clinical Update on SRF388 at American Society of Clinical Oncology Annual Meeting
04:15pm, Wednesday, 27'th Apr 2022
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microen
Foreshadowing Stock: Surface Oncology, Inc. (NASDAQ:SURF), Pinterest, Inc. (NYSE:PINS)
09:16am, Monday, 14'th Mar 2022 Stock Equity
Surface Oncology, Inc. (NASDAQ:SURF) with the stream of -4.17% also noticed, India Pinterest, Inc. (NYSE:PINS) encountered a rapid change of -3.51% in the last hour of Friday’s trading session. Surface … The post Foreshadowing Stock: Surface Oncology, Inc. (NASDAQ:SURF), Pinterest, Inc. (NYSE:PINS) appeared first on Stocks Equity .
Trading Penny Stocks? Top Stock Market News for March 11th, 2022
09:30am, Friday, 11'th Mar 2022
What you need to know about trading penny stocks on March 11th The post Trading Penny Stocks? Top Stock Market News for March 11th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Informat
Surface Oncology GAAP EPS of -$0.52 misses by $0.43, revenue of $0.15M misses by $16.18M
12:42pm, Wednesday, 02'nd Mar 2022 Seeking Alpha
Surface Oncology press release (SURF): Q4 GAAP EPS of -$0.52 misses by $0.43.Revenue of $0.15M (-99.8% Y/Y) misses by $16.18M.Shares +1.65% PM.
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2021
12:10pm, Wednesday, 02'nd Mar 2022 GlobeNewswire
Continued progress advancing next-generation antibody portfolio, with ongoing clinical trials evaluating the broad potential of SRF388 and SRF617 across multiple tumor types
GlaxoSmithKline PLC – Consensus Indicates Potential 16.0% Upside
10:34am, Wednesday, 02'nd Mar 2022 DirectorsTalk
GlaxoSmithKline PLC found using ticker (GSK) have now 2 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The range between the high target price and low target price is between 51.5 and 45.64 with a mean TP of 48.57. With the stocks previous close at 41.86 this now indicates there is a potential upside of 16.0%. The 50 day MA is 44.16 and the 200 day MA is 41.31. The company has a market capitalisation of $105,612m. You can visit the company''s website by visiting: https://www.gsk.com [stock_market_widget type="chart" template="basic" color="green" assets=GSK" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $122,541m based on the market concensus. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.